Activin-binding glycoprotein that inhibits myostatin, researched for promoting muscle growth, reducing fibrosis, and supporting tissue remodeling.
Last Updated: May 2026
Follistatin is an activin-binding glycoprotein researched for myostatin inhibition, muscle growth promotion, fibrosis reduction, and tissue remodeling support. It is one of the more pharmacologically distinct compounds in the tissue-repair category — a glycoprotein rather than a small peptide, with substantially larger molecular weight and structural complexity. Several follistatin variants exist (FS-288, FS-315, FS-344) with different tissue-binding properties. Follistatin is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.
Follistatin is an activin-binding glycoprotein that neutralizes myostatin (also called GDF-8), the TGF-β family member that negatively regulates skeletal muscle mass. By sequestering myostatin and related TGF-β superfamily members (activin A, GDF-11), follistatin removes the brake on muscle growth and supports anabolic muscle remodeling. The biological effect is well-characterized — myostatin knockout produces dramatically enhanced muscle mass in animal models, and natural human follistatin variants are associated with muscle mass variation. Several follistatin variants (FS-288, FS-315, FS-344) have different tissue-binding properties. Evidence level: Established biology (myostatin pathway); preclinical extensive; limited human clinical research.
Preclinical studies have demonstrated substantial muscle mass increases through myostatin inhibition across rodent and other animal models. Phase 1/2 clinical research has been conducted in Duchenne muscular dystrophy and inclusion body myositis contexts with limited efficacy signals. Gene therapy approaches to follistatin delivery (AAV-follistatin) are in earlier-stage research for muscular dystrophy indications. Recombinant follistatin protein therapy has not advanced to formal Phase 3 approval. Evidence level: Preclinical extensive; Phase 1/2 in muscular dystrophy contexts; no Phase 3 approval.
Follistatin is mechanistically distinct from BPC-157 and TB-500 — its primary effect is muscle-specific via myostatin inhibition rather than broad tissue repair, and it is a much larger glycoprotein rather than a small peptide.
| Compound | Mechanism | Compound class | Primary tissue |
|---|---|---|---|
| Follistatin | Myostatin/activin binding | Glycoprotein (large) | Skeletal muscle |
| BPC-157 | Multi-pathway tissue protection | 15-AA peptide | Broad tissue repair |
| TB-500 | Actin binding | 17-AA peptide fragment | Broad tissue repair |
| Myostatin-targeting biologics | Direct myostatin antibody/binding | Antibody therapeutics | Muscle (similar target) |
Side effects in available clinical research and community-reported research use are generally mild — injection-site reactions are the most common report. The myostatin inhibition mechanism raises theoretical concerns about effects on muscle composition, cardiac muscle (myostatin is expressed in cardiac tissue), and reproductive function (activin is involved in gonadotropin regulation). Long-term safety at sustained dosing is not characterized at Western RCT standards. Evidence level: Phase 1/2 safety; long-term and cardiac unestablished; theoretical concerns reflect mechanism biology.
Follistatin is not approved for any medical indication anywhere in the world as of May 2026. Phase 1/2 clinical research has been conducted in muscular dystrophy contexts without advancing to Phase 3 approval. The compound was not specifically included in the April 2026 FDA Category 2 removals. Follistatin is sold strictly as a research-use-only material by third-party laboratories. Regulatory context in are peptides legal regulatory status by country.
Follistatin is a glycoprotein with substantially larger molecular weight and structural complexity than small peptides — synthesis, expression (typically recombinant), and quality control are fundamentally different and more variable. Different follistatin variants (FS-288, FS-315, FS-344) have different properties. Independent HPLC, mass spectrometry, and ideally glycosylation analysis are essential — though research-grade analytical standards may not fully match pharmaceutical-grade glycoprotein verification. Guidance in how-to-test-peptides hub (note: peptide-specific guidance does not all directly apply to glycoproteins).
Peptigrity purchases Follistatin vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The glycoprotein nature limits the discriminating power of standard peptide tests. Methodology in how we calculate trust scores.
Follistatin neutralizes myostatin to remove the natural brake on muscle growth, producing substantial muscle mass increases in preclinical models. Human clinical evidence is more limited, with Phase 1/2 research in muscular dystrophy contexts not advancing to Phase 3 approval.
Follistatin is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.
No active formal clinical development program has advanced Follistatin to FDA approval as of May 2026. Phase 1/2 work in muscular dystrophy has not produced sufficient efficacy signal to advance to Phase 3.
Myostatin is expressed in cardiac tissue as well as skeletal muscle, so the myostatin inhibition mechanism raises theoretical concerns about cardiac effects. Clinical substantiation of these concerns is limited but the mechanism biology supports caution. Anyone considering Follistatin use should consult a licensed physician about the underlying pathway biology.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Note that for a glycoprotein, standard peptide testing has less discriminating power; pharmaceutical-grade glycosylation analysis is not standard in research-grade markets. Verify which follistatin variant (FS-288, FS-315, FS-344) is being sold. COA interpretation in red flags in peptide certificates of analysis.
No. Follistatin is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing varies widely. Anyone considering use should consult a licensed physician.
Myostatin inhibitors including Follistatin are on the WADA Prohibited List (Section S4.5 — Myostatin Function Modifiers). For drug-testing context, see do peptides show up on drug tests.
This section is for educational and informational purposes only and does not constitute medical advice. Follistatin is not approved by the FDA or any major Western regulator for human use, and it is prohibited by WADA as a myostatin function modifier. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.